Active, not recruitingNot applicableNCT06150820

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

Studying Glycogen storage disease due to acid maltase deficiency, late-onset

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Astellas Gene Therapies
Principal Investigator: Medical Director
Astellas Gene Therapies
Intervention: No Intervention(other)
Enrollment: 119 enrolled
Eligibility: 16-69 years · All sexes
Timeline: 2024 – 2027

Study locations (20)

Emory Clinic, Atlanta, Georgia, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
University of Michigan, Ann Arbor, Michigan, United States
Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
University of Cincinnati, Cincinnati, Ohio, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
University of UTAH - PPDS, Salt Lake City, Utah, United States
Lysosomal and Rare Diseases Research and Treatment Center, Inc., Fairfax, Virginia, United States
AU61003, Adelaide, Australia
AU61001, Herston, Australia
BR55003, Flamengo, Brazil
BR55002, Porto Alegre, Brazil
BR55001, São Paulo, Brazil
+5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06150820 on ClinicalTrials.gov

Other trials for Glycogen storage disease due to acid maltase deficiency, late-onset

Additional recruiting or active studies for the same condition.

See all trials for Glycogen storage disease due to acid maltase deficiency, late-onset →

← Back to all trials